Schizophrenia (CIAS)

You are here

Developing an innovative treatment for CIAS


More than 45 million people worldwide live with schizophrenia, a severe cerebral disorder that causes auditory and visual hallucinations and paranoid delusions and affects the way people manage emotions and relate with others. There are three subtypes of symptoms: positive (visual and auditory senses are affected), negative (lower social interaction), and cognitive impairment (executive function disorders, memory and attention).

Current antipsychotic drugs address mainly the positive symptoms, but the negative symptoms and cognitive impairment still require suitable pharmacological approaches and are thus an unmet medical need. Around 75% of patients with schizophrenia suffer from Cognitive Impairment Associated with Schizophrenia (CIAS).

Iproteos’ lead candidate is a first-in-class drug that addresses CIAS through a novel mechanism of action (MoA). The drug is currently finishing Regulatory Preclinical Trials, after having demonstrated in vivo activity and no toxicity, and will enter into Phase I studies in 2019.